Unicycive Therapeutics Inc Dossier - Source-backed chat

Unicycive Therapeutics Inc

UNCYNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.52

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.70Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $128.6M

Enterprise Value $84.4M

Shares Outstanding 29.3M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Unicycive Therapeutics is a highly asymmetric, late-clinical-stage biopharmaceutical company on the cusp of a major regulatory catalyst. The company's lead asset, oxylanthanum carbonate (OLC), is an oral phosphate binder designed to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. OLC addresses a massive unmet need by offering up to a 4x reduction in daily pill burden compared to legacy binders, which is expected to significantly improve patient adherence. Following a manufacturing-related Complete Response Letter (CRL) in June 2025, Unicycive successfully resolved the third-party CDMO issues and resubmitted its NDA, which was accepted by the FDA as a Class II resubmission with a PDUFA target action date of June 29, 2026. Crucially, the FDA raised no concerns regarding OLC's preclinical, clinical, or safety data in the original review. Backed by a strong cash position of $57.1 million (runway into 2027) and a clear commercial launch strategy targeting high-volume prescribers and large dialysis organizations, Unicycive represents a compelling buy ahead of its imminent regulatory decision.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$13.00

Mean target$38.59

High · most bullish analyst$90.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.00

The FDA issues another CRL or delays approval due to lingering manufacturing/compliance issues at the CDMO (Shilpa Medicare) or pre-approval inspection findings. This delays commercialization into late 2027, forcing Unicycive to raise highly dilutive capital to sustain operations, severely impairing equity value.

Base CaseCentral scenario

$18.00

OLC receives FDA approval on the June 29, 2026 PDUFA date. Commercial launch begins in late 2026, with steady, progressive market penetration among the targeted 2,100 high-volume prescribers. Cash reserves of $57.1 million successfully fund operations into 2027, covering the initial launch phase. The company achieves moderate market share in the $2B+ hyperphosphatemia market, with stock valuation aligning with consensus analyst targets.

Bull CaseUpside scenario

$37.00

The FDA approves OLC on or before the June 29, 2026 PDUFA date. Unicycive executes a flawless commercial launch, leveraging its UniSource hub for reimbursement support. Rapid adoption by major dialysis organizations and high-prescribing nephrologists drives steep revenue growth in late 2026 and 2027, validating OLC's best-in-class pill burden reduction profile. The company secures a lucrative ex-U.S. commercialization partnership, extending its cash runway indefinitely and allowing the reactivation of the UNI-494 program.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Imminent high-impact regulatory catalyst with a PDUFA date of June 29, 2026.
De-risked clinical profile: FDA raised zero concerns regarding OLC's preclinical, clinical, or safety data in the original NDA review.
Strong value proposition: OLC offers a 4x reduction in daily pill burden (by volume) compared to the most prescribed legacy phosphate binders, addressing the primary cause of patient non-adherence.
Robust cash position of $57.1 million as of mid-May 2026, providing a runway into 2027 to support launch preparations.
Concentrated commercial model targeting approximately 2,100 high-volume prescribers and major dialysis chains, minimizing initial sales force requirements.

Key Investment Risks

Single-asset concentration risk in the near term, as UNI-494 has been deprioritized to conserve resources.
Dependence on third-party CDMOs (such as Shilpa Medicare) for commercial manufacturing and validation, which previously caused regulatory delays.
Commercial execution risk in a market historically dominated by established legacy binders (e.g., Renvela, Fosrenol, Velphoro, Auryxia).
Potential for future equity dilution if the commercial launch requires more capital than currently budgeted.

Thesis Invalidation Triggers

Receipt of a second Complete Response Letter (CRL) or a major regulatory delay from the FDA on or around June 29, 2026.
Failure to commission the dedicated commercial manufacturing block or validate exhibit batches at Shilpa Medicare on schedule.
A significant cash burn acceleration that shortens the projected runway to under 12 months before achieving commercial revenue.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.